Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) Income from Continuing Operations (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Income from Continuing Operations for 6 consecutive years, with 6718000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 57.84% to 6718000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 33617000.0 through Dec 2025, up 50.41% year-over-year, with the annual reading at 33617000.0 for FY2025, 50.41% up from the prior year.
  • Income from Continuing Operations hit 6718000.0 in Q4 2025 for Bolt Biotherapeutics, up from 7226000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 6718000.0 in Q4 2025 to a low of 27157000.0 in Q4 2021.
  • Historically, Income from Continuing Operations has averaged 17560600.0 across 5 years, with a median of 17980000.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 113.27% in 2021 and later soared 59.37% in 2025.
  • Year by year, Income from Continuing Operations stood at 27157000.0 in 2021, then increased by 26.37% to 19997000.0 in 2022, then grew by 10.47% to 17903000.0 in 2023, then grew by 10.99% to 15936000.0 in 2024, then surged by 57.84% to 6718000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for BOLT at 6718000.0 in Q4 2025, 7226000.0 in Q3 2025, and 8611000.0 in Q2 2025.